Will ESTA's Q1 2025 earnings beat forecasts?

**Establishment Labs' (ESTA) Q1 2025 earnings are likely to beat forecasts**, based on the following points:

1. **Revenue Outlook**: ESTA anticipates Q1 2025 revenue to be approximately $41.4 million. This is slightly below the estimated revenue of $42.37 million forecasted by analysts. However, considering the company's full-year guidance of $205-210 million for 2025, the Q1 projection aligns closely with the overall financial outlook.

2. **Market Performance**: The US launch of Motiva products has shown significant traction, with March orders exceeding 100 per day. This strong market penetration suggests that the company's revenue for the quarter could be higher than anticipated.
3. **Financial Metrics**: ESTA has reported a net loss reduction and an increase in gross profit margin, indicating improved operational efficiency. Additionally, the company expects to turn EBITDA positive in 2025 and achieve cash flow positivity by 2026, which implies a financial trajectory that could support exceeding earnings expectations.
4. **Strategic Positioning**: The company's strategic investments and cost control measures have led to a reduction in operating expenses and improved gross margins. These efforts could contribute to better-than-expected earnings due to enhanced operational efficiency.
5. **Industry Trends**: The medical technology sector is growing, and ESTA's focus on women's health and aesthetics positions it well within a expanding market. This favorable industry trend could lead to stronger-than-expected revenue and earnings.

In conclusion, while the estimated revenue for Q1 2025 is slightly below forecasted figures, the company's strong market performance, financial metric improvements, strategic positioning, and favorable industry trends suggest that ESTA's Q1 2025 earnings are likely to beat forecasts.